Building a healthcare board that actually helps

What most boards do wrong

The default startup board — three investors, two founders, one independent — is optimized for oversight, not counsel. In healthcare, where regulatory, clinical, and payer dynamics dominate, this is often the wrong configuration.

A better default

Reserve at least one independent seat for a senior operator with deep domain experience — a former CMO of a health system, a payer executive, or an experienced regulatory leader. This one seat can materially change outcomes.

The board meeting itself

Ship the deck 72 hours in advance. Spend meeting time on the top three open questions, not on the historical numbers. Rotate the specific topics deep-dived each quarter.

What to protect

Founder time, decision speed, and honesty. A board that erodes any of these is a board that will hurt the company, however well-intentioned.

The founder-clinician partnership

The strongest teams we have backed pair a founder who has operated at scale with a clinician who is still practicing. The tension between the two is the point. The operator wants to ship. The clinician wants to be right. The product that emerges from that tension is better than either would have built alone.

Teams that hire the clinician as an advisor rather than a co-founder consistently underestimate how much clinical judgment their product has to encode.

Hiring the first ten

The first ten hires set the ceiling on everything that follows. In healthtech, we push founders to over-index on hires who have shipped in a regulated environment before, even if it means paying more or waiting longer. The velocity gain from a team that has already survived one audit is enormous.

What we are watching from the studio

Inside the venture studio, we are prioritizing three build areas connected to this thesis: the workflow substrate under clinical AI (consent, provenance, routing, human-in-the-loop review); the measurement layer that translates model behavior into a claim a payer or regulator can act on; and the operational tooling for the specialty clinics and virtual-first practices that will be the first commercial buyers of the next wave.

We are less interested in another general-purpose copilot. We are more interested in the boring infrastructure that makes ten specialized copilots safe to run at once.

Why the incumbent playbook keeps failing

The instinct of a large healthcare organization is to procure a platform, run a governance committee, and let the technology diffuse through mandate. That playbook worked for imaging PACS in the 2000s. It has failed, visibly and expensively, for the current wave of AI-native tooling. The reason is structural: modern systems have to be tuned to the institution's own data, workflow, and liability posture, and that tuning is a product-engineering exercise, not a procurement exercise.

Founders who understand this shape their commercial motion around a technical champion inside the health system — usually a CMIO, a service-line chief, or a director of quality — and treat every deployment as a co-development contract with clear evaluation gates.

The corollary is that the sales cycle is longer than any founder wants to admit, and the winners raise capital that lets them survive twelve months of pilot without a single dollar of expansion revenue.

The field notes

Across the last quarter we sat in on operating reviews with fourteen portfolio and prospective teams working adjacent problems. Three patterns kept surfacing. First, the teams that moved fastest were not the ones with the deepest research bench — they were the ones with the shortest feedback loop between a real clinical user and the roadmap. Second, the winners had unusually opinionated evaluation harnesses. Third, none of them treated regulatory strategy as a phase; they treated it as a running conversation with the product.

What follows is a longer look at what we saw, what we think it implies for founders, and where we are actively deploying capital and studio effort in the coming twelve months.